Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Neuroprotection' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Neuroprotection Drugs, Markets and Companies |
March 2010 | £2970 | 100 % |
|
Parkinson's Disease - Evidence Of Neuroprotection Essential To Progress Treatment Dynamics Stakeholder Insight |
December 2007 | £5020 | 92 % |
|
Neurodegenerative Diseases Next-Generation Drugs for Four Major Disorders |
December 2008 | £2475 | 35 % |
|
Competitor Analysis VEGF and VEGF-R Agonists and Antagonists |
September 2009 | £540 | 34.5 % |
|
Embolic Protection Device Clinical Trial Analysis |
July 2009 | £660 | 30.8 % |
|
Pipeline Insight: Acute Stroke Commercial Risk Offsets High Unmet Need |
May 2008 | £3965 | 20.65 % |
|
Competitor Analysis: Neurotrophic Growth Factors |
December 2009 | £360 | 20 % |
|
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics 2009-2023 |
January 2009 | £1499 | 16.1 % |
|
Stakeholder Insight: Acute Stroke - TPA spurs infrastructure changes for the better Healthcare |
October 2007 | £5020 | 15.75 % |
|
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth |
August 2006 | £5745 | 15.4 % |
|
Nitric Oxide Therapeutics, Markets and Companies |
March 2010 | £1850 | 15.05 % |
|
Alzheimer's disease |
March 2010 | £2115 | 13.3 % |
|
Alzheimer's disease New drugs, markets and companies |
December 2008 | £1980 | 12.95 % |
|
Alzheimer Disease New Drugs, Markets and Companies |
May 2009 | £1850 | 12.6 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
February 2010 | £2115 | 12.25 % |
|
Alzheimer's disease New Drugs, Markets and Companies |
October 2009 | £1980 | 12.25 % |
|
Alzheimer's Disease New Drugs, Markets and Companies |
October 2009 | £1980 | 12.25 % |
|
Cell Therapy Technologies, Markets and Companies |
March 2010 | £3300 | 9.8 % |
|
Parkinson's Disease Market analysis and forecasts 2008-2012, 2017 & 2022 |
January 2008 | £1499 | 8.4 % |
|
Drug Delivery to Central Nervous System Diseases Technologies, Markets and Companies |
February 2010 | £1850 | 6.65 % |
|
Drug Delivery in Central Nervous System Diseases Technologies,Markets and Companies |
October 2009 | £1650 | 6.65 % |
|
Drug Delivery to CNS |
March 2010 | £1850 | 6.65 % |
|
Gene Therapy Technologies, Markets and Companies |
March 2010 | £2970 | 4.55 % |
|
Nanobiotechnology Applications, Markets and Companies |
March 2010 | £2970 | 3.85 % |
